MovDisordV3, PascalFrancis, Curation, bibRecord, 001291

Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Identifieur interne : 001291 ( PascalFrancis/Curation ); précédent : 001290; suivant : 001292

Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Auteurs : Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël]

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0435108

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Stimulant dopaminergique, Fatigue, Somnolence.

English descriptors

KwdEn :
- Dopamine agonist, Fatigue, Nervous system diseases, Parkinson disease, Somnolence.

Abstract

Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30-second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age-matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between-group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease`
A11	`01`	`1`		`@1 OVED (Daniel)`
A11	`02`	`1`		`@1 ZIV (Ilan)`
A11	`03`	`1`		`@1 TREVES (Therese A.)`
A11	`04`	`1`		`@1 PALEACU (Diana)`
A11	`05`	`1`		`@1 MELAMED (Eldad)`
A11	`06`	`1`		`@1 DJALDETTI (Ruth)`
A14	`01`			`@1 Department of Neurology, Robin Medical Center, Beilinson Campus @2 Petah Tiqwa @3 ISR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Neurology Service and Memory Clinic, Abarbanel Mental Health Center @2 Bat Yam @3 ISR @Z 4 aut.`
A20				`@1 1257-1261`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000142193570390`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 06-0435108`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30-second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age-matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between-group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 09`
C03	`03`	`X`	`ENG`	`@0 Dopamine agonist @5 09`
C03	`03`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 09`
C03	`04`	`X`	`FRE`	`@0 Fatigue @5 10`
C03	`04`	`X`	`ENG`	`@0 Fatigue @5 10`
C03	`04`	`X`	`SPA`	`@0 Fatiga @5 10`
C03	`05`	`X`	`FRE`	`@0 Somnolence @5 11`
C03	`05`	`X`	`ENG`	`@0 Somnolence @5 11`
C03	`05`	`X`	`SPA`	`@0 Somnolencia @5 11`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 289`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A30

Links to Exploration step

Pascal:06-0435108

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease</title>
<author><name sortKey="Oved, Daniel" sort="Oved, Daniel" uniqKey="Oved D" first="Daniel" last="Oved">Daniel Oved</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Ziv, Ilan" sort="Ziv, Ilan" uniqKey="Ziv I" first="Ilan" last="Ziv">Ilan Ziv</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Treves, Therese A" sort="Treves, Therese A" uniqKey="Treves T" first="Therese A." last="Treves">Therese A. Treves</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Paleacu, Diana" sort="Paleacu, Diana" uniqKey="Paleacu D" first="Diana" last="Paleacu">Diana Paleacu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology Service and Memory Clinic, Abarbanel Mental Health Center</s1>
<s2>Bat Yam</s2>
<s3>ISR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0435108</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0435108 INIST</idno>
<idno type="RBID">Pascal:06-0435108</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A30</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001291</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease</title>
<author><name sortKey="Oved, Daniel" sort="Oved, Daniel" uniqKey="Oved D" first="Daniel" last="Oved">Daniel Oved</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Ziv, Ilan" sort="Ziv, Ilan" uniqKey="Ziv I" first="Ilan" last="Ziv">Ilan Ziv</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Treves, Therese A" sort="Treves, Therese A" uniqKey="Treves T" first="Therese A." last="Treves">Therese A. Treves</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Paleacu, Diana" sort="Paleacu, Diana" uniqKey="Paleacu D" first="Diana" last="Paleacu">Diana Paleacu</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology Service and Memory Clinic, Abarbanel Mental Health Center</s1>
<s2>Bat Yam</s2>
<s3>ISR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Fatigue</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Somnolence</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Stimulant dopaminergique</term>
<term>Fatigue</term>
<term>Somnolence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30-second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age-matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between-group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P <  0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OVED (Daniel)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZIV (Ilan)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TREVES (Therese A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PALEACU (Diana)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MELAMED (Eldad)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DJALDETTI (Ruth)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Robin Medical Center, Beilinson Campus</s1>
<s2>Petah Tiqwa</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology Service and Memory Clinic, Abarbanel Mental Health Center</s1>
<s2>Bat Yam</s2>
<s3>ISR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1257-1261</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000142193570390</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0435108</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30-second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age-matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between-group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P <  0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Fatigue</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Fatigue</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fatiga</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Somnolence</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Somnolence</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Somnolencia</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>289</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001291 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001291 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0435108
   |texte=   Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri